Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CCNK | O75909 | 1/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | ADAMTS7 | Q9UKP4 | 1/20 | 0.38 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | BCR | P11274 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20135211 | 0.91 | KMT2A (0.39) | MEN1KMT2AACACBACACAMMP2 | |
| SCHEMBL20135214 | 0.91 | KMT2A (0.39) | MEN1KMT2AACACBACACAMMP2 | |
| SCHEMBL20134877 | 0.80 | MEN1 (0.65) | MEN1KMT2AHSD11B1MGLL | |
| SCHEMBL20134876 | 0.80 | MEN1 (0.65) | MEN1KMT2AHSD11B1MGLL | |
| SCHEMBL20134801 | 0.79 | KDM5A (0.39) | MEN1KMT2AACACBACACAMMP2 | |
| SCHEMBL20134802 | 0.79 | KDM5A (0.39) | MEN1KMT2AACACBACACAMMP2 | |
| SCHEMBL20134790 | 0.78 | TLR8 (0.43) | MEN1KMT2AACACBACACACRBN | |
| SCHEMBL20134970 | 0.78 | MGLL (0.39) | MEN1KMT2AADAMTS7MMP2MMP9 | |
| SCHEMBL20134973 | 0.78 | MGLL (0.39) | MEN1KMT2AADAMTS7MMP2MMP9 | |
| SCHEMBL20134793 | 0.78 | TLR8 (0.43) | MEN1KMT2AACACBACACACRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | MEN1 3735/4885KMT2A 2568/4885CCNK 2686/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | MEN1 2913/4885KMT2A 2539/4885CCNK 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.